Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Up 8.1% in January

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 9,500,000 shares, a growth of 8.1% from the December 31st total of 8,790,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is currently 5.7 days. Currently, 7.6% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of brokerages have recently commented on HALO. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Piper Sandler boosted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday. Finally, JMP Securities boosted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $60.89.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $56.28 on Tuesday. The firm’s 50-day moving average price is $50.82 and its 200-day moving average price is $54.33. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a market cap of $7.16 billion, a PE ratio of 18.64, a PEG ratio of 0.43 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RPg Family Wealth Advisory LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $1,886,000. Segall Bryant & Hamill LLC lifted its holdings in Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after acquiring an additional 49,856 shares during the period. Retirement Systems of Alabama boosted its position in Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares during the last quarter. South Street Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $9,812,000. Finally, Creative Planning increased its position in shares of Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after purchasing an additional 11,249 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.